An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’
AI disclosure
Summary
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.